TuHURA raises $12.6M in private placement, $3M from warrants, tied to Phase 3 & merger milestones

TuHURA Biosciences, Inc./NV

• Total offering $12.6M (4.76M shares + warrants at $2.65/unit). Initial closing $2.23M.
• $9M purchased in four tranches tied to milestones: FDA partial clinical hold lift, Phase 3 start, Kineta merger close.
• Remaining $3.7M due by Dec 31, 2025. Also received $3.0M from Feb 2025 warrant exercise.
• Proceeds to fund Kineta merger closing, Phase 3 trial of IFx-2.0, and advancement of KVA12123 to Phase 2.
• Warrants exercisable at $3.3125, 5-year term, subject to authorized share increase.